iHealthScreen was established in the United States with initial funding of over $2.5 million from the NIH and is currently in the process of securing an additional $6.5 million through private investors and continued NIH support. The company was founded by Dr. Alauddin Bhuiyan, an Associate Professor at the Icahn School of Medicine at Mount Sinai, who holds a Ph.D. from the University of Melbourne and is a recipient of the prestigious Endeavour Fellowship (Australia Awards). He has also served as a visiting scholar at Harvard University. It focuses on developing AI-powered eye screening solutions for detecting conditions such as Diabetic Retinopathy, Age-related Macular Degeneration (AMD), and Glaucoma. The company also works on predictive tools, digital prescription platforms, and educational technologies. To support growth and scale its operations, iHealthScreen has a dedicated team in Bangladesh operating under iHealthScreen Bangladesh Ltd., collaborating closely with the Diabetic Association of Bangladesh (BADAS) and various governmental and non-governmental organizations.
About the Role iHealthScreen Bangladesh Ltd., a forward-thinking company at the intersection of technology, healthcare, and education, is looking for...
